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ICOS (inducible co-stimulator molecule) is a T cell
encoded member of the extended B7/CD28 superfamily
that is up-regulated upon early T cell activation.
Previous studies have shown that higher ICOS expres-
sion on circulating T cells, post treatment with ipilimu-
mab, is associated with better clinical outcome. In
complementary pre-clinical studies, efficacy observed
with a whole cell vaccine consisting of ICOS-L expres-
sing B16 melanoma (IVAX) suggests that agonism of
this pathway could provide therapeutic benefit in the
cancer setting.
We have generated a panel of anti-ICOS monoclonal
antibodies with in vitro agonist properties. These lead
agonist mAbs have been shown to be efficacious both as
monotherapies in multiple syngeneic tumor models and
in combination with an anti-PD1 antibody. Mechanistic
studies that demonstrate tumor regression is associated
with enhanced ratios of cytotoxic CD8/regulatory
T (Tregs) cells as well as preferential reduction in ICOS
high Tregs in the tumor microenvironment have
informed the selection of optimal Fc regions for clinical
development.
Jounce is now developing a high affinity humanized
agonist monoclonal antibody to be tested as both a
monotherapy as well as in combination with other
T cell checkpoints in solid tumor indications.
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